Boardroom Alpha
Start trial
Boardroom Alpha
SRTA · Additional Proxy Materials (DEFA14A) · Filed April 14, 2026

Strata Critical Medical Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 14, 2026
Ticker
SRTA
Accession
0001140361-26-014532
Strata Critical Medical Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Strata Critical Medical seeks two Class II director seats, Deloitte audit ratification, and executive-compensation advisory; board urges For all.

About Strata Critical Medical Inc
Market cap
$542M
1Y TSR
+46.9%
3Y TSR
+15.1%
Board grade
C
Sector
Industrials
CEO
Melissa M Tomkiel
Last annual meeting: May 28, 2026 · View full Strata Critical Medical Inc profile →
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
 
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.  )
Filed by the Registrant ☒
Filed by a Party other than the Registrant  ☐
Check the appropriate box:
 ☐
Preliminary Proxy Statement
 ☐
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 ☐
Definitive Proxy Statement
☒
Definitive Additional Materials
 ☐
Soliciting Material Pursuant to §240.14a-12
 
Strata Critical Medical, Inc
(Name of Registrant as Specified In Its Charter)
 
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
☒
No fee required.
 ☐
Fee paid previously with preliminary materials.
 ☐
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.


 Your Vote Counts!  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  QAARV1-P12345  You invested in STRATA CRITICAL MEDICAL, INC. and it's time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on May 28, 2026.  Get informed before you vote  View the Notice & Proxy Statement, Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 14, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Ricky Campana  P.O. Box 123456  Suite 500  51 Mercedes Way  Edgewood, NY 11717  1 OF  322,224  148,294  4  30#  XXXX XXXX XXXX XXXX  V2.1  STRATA CRITICAL MEDICAL, INC.  2026 Annual Meeting  Vote by May 27, 2026  11:59 PM ET  STRATA CRITICAL MEDICAL, INC. 666 THIRD AVENUE, 25TH FLOOR NEW YORK, NEW YORK 10017  Vote Virtually at the Meeting*  May 28, 2026  9:00 AM EDT  Virtually at:  www.virtualshareholdermeeting.com/SRTA2026  *Please check the meeting materials for any special requirements for meeting attendance. 
 

 THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.  Vote at www.ProxyVote.com  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  QAARV2-P12345  Elect Class II Directors for terms expiring in 2029.  Nominees:  William A. Heyburn 02) Andrew Lauck  For  2. Ratify Appointment of Independent Registered Public Accounting Firm for 2026 (Deloitte & Touche LLP).  For  3. Advisory Vote on the Compensation of our Named Executive Officers.  For  NOTE: Such other business as may properly come before the meeting or any adjournment thereof.  Voting Items  Board Recommends  Control # XXXX XXXX XXXX XXXX  SHARE CLASSES REPRESENTED FOR VOTING  THE COMPANY NAME INC. - COMMON ASDFGHJKL 123456789.1234  THE COMPANY NAME INC. - CLASS A  123456789.1234  THE COMPANY NAME INC. - CLASS B  123456789.1234  THE COMPANY NAME INC. - CLASS C  123456789.1234  THE COMPANY NAME INC. - CLASS D  123456789.1234  THE COMPANY NAME INC. - CLASS E  123456789.1234  THE COMPANY NAME INC. - CLASS F  123456789.1234  THE COMPANY NAME INC. - 401 K  123456789.1234  1.00000  322,224  148,294  CLT ID 
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Strata Critical Medical Inc (SRTA)

Continue researching
Reference

Frequently asked questions

When did Strata Critical Medical Inc file this DEFA14A?
Strata Critical Medical Inc (SRTA) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 14, 2026. The accession number assigned by EDGAR is 0001140361-26-014532.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Strata Critical Medical seeks two Class II director seats, Deloitte audit ratification, and executive-compensation advisory; board urges For all. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Strata Critical Medical Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Strata Critical Medical Inc has filed under CIK 1779128, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer